“…Recombinant human GCSF is clinically used to prevent neutropenia, due to its effects on neutrophil mobilization and maturation [ 32 ]. GCSF/CD114 signaling has also been investigated as a modulator of neuronal survival, synaptic plasticity [ 6 , 28 , 29 , 30 , 31 ], and cancer [ 7 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ]. Specifically, CD114 has been put forward as a marker to identify CSC subpopulations associated with tumorigenicity, metastasis, and resistance to treatment [ 7 , 9 , 10 ].…”